+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Infant Formula - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2027-2032)

  • PDF Icon

    Report

  • 420 Pages
  • October 2026
  • Region: Global
  • Mordor Intelligence
  • ID: 6292711
The infant formula market size is projected to expand from USD 52.47 billion in 2026 to USD 54.52 billion in 2027, to USD 66.05 billion by 2032, registering a CAGR of 3.91% between 2027 and 2032. This report is Segmented by Type (Infant Milk, Follow-Up Milk, and More), Category (Standard, Premium, and Therapeutic), Nature (Conventional and Organic), Form (Powder and Liquid), Distribution Channel (Supermarkets/Hypermarkets, Pharmacies, and More), and Geography (North America, and More. The Market Sizes and Forecasts are Provided in Terms of Value (USD) and Volume (Units) for all the Above Segments.

Global Infant Formula Market Trends and Insights

Increasing Participation of Women in the Workforce

Maternal employment remains a durable driver for the infant formula market because it increases the need for flexible feeding routines. In 2025, 68.00% of U.S. mothers with children under 6 were in the labor force. This group has a close connection with the use of prepared feeding products when time away from home is limited. In large Chinese cities, more than 52% of mothers returned to work within 6 months of giving birth, which shortens exclusive breastfeeding periods. Workforce participation in India supports formula uptake in Tier 2 cities as modern retail expands. Ready-to-feed and liquid options can carry a 30% to 40% price premium, which supports value growth when formula volumes remain stable.

Product Innovation and Advances in Infant Formula Composition

Ingredient development is making clinical evidence more important in the infant formula market. A 2025 trial reported that a formula with 7 HMO types, bovine milk oligosaccharides, and B. infantis supported age-appropriate growth and improved gut-comfort outcomes within 19 days. Nestlé introduced Wyeth Illuma as its first HMO-containing liquid formula in Mainland China. Danone launched formulas containing 5 HMO types and Bifidobacterium breve M-16, supported by evidence on infant body mass index outcomes. The expansion of evidence around HMOs, GOS, MFGM, and synbiotic blends is raising the standard for new product development. Tighter rules on health claims can limit the ways companies translate clinical evidence into consumer communications, particularly in Europe.

Increasing Preference for Breastfeeding

Breastfeeding promotion can limit demand growth in the infant formula market, particularly in countries with strong public health programs. The 2025 Global Breastfeeding Scorecard reported a 44:1 return on investment from breastfeeding support through health-care savings and productivity gains. In May 2025, the World Health Assembly renewed the global nutrition plan through 2030 and asked member states to address digital promotion of breast-milk substitutes. The policy direction is relevant in countries working toward the World Health Organization target of 60% exclusive breastfeeding during the first 6 months. A 2025 study found that breastfeeding increased among some formula-dependent U.S. households during constrained formula availability, showing that part of demand can shift. This may reduce digital customer acquisition opportunities in places where breastfeeding promotion and online retail are both expanding.

Other drivers and restraints analyzed in the report include:
  • Increasing Demand for Specialized and Functional Infant Formula
  • Rising Awareness of Infant Nutrition and Development
  • Stringent Regulations Governing Infant Formula Composition and Marketing

Segment Analysis

Growing-Up Milk Formula held 45.36% of value in 2026 and is projected to grow at a 5.35% CAGR through 2032. This gives the segment the leading position by current value and forecast growth. The product extends the relationship between nutrition brands and families beyond the first birthday. It is commonly presented as a nutritional option for toddlers rather than as a substitute for milk. The segment also operates under lighter marketing restrictions than Stage 1 and Stage 2 formulas.

Infant Milk Formula for ages 0 to 6 months remains central to early brand selection in the infant formula industry. It also carries the highest clinical scrutiny and recall exposure because it serves the youngest infants. Follow-Up Milk Formula for ages 6 to 12 months has lower demand in countries where solid foods are introduced early. Japan and Germany are examples of markets with established weaning practices that can compress demand for this stage. Specialty formulas have the highest unit margins across product types and receive substantial research and development attention.

Premium Formula held 56.48% of value in 2026 and is forecast to grow at a 4.59% CAGR through 2032. Its position reflects spending on products associated with ingredient quality and clinical support. Higher household income has been an important factor in China’s movement toward premium products. China’s premium segment continues to benefit from the association between higher-value products and clinical ingredient quality. New standard compliance has also made speed of reformulation important for competing brands.

Standard Formula remains important in price-sensitive parts of South Asia, Southeast Asia, and Sub-Saharan Africa. It gives first-time users access to products at lower price points. Therapeutic formulas remain small by volume but have more stable demand when selected through health-care professionals. This clinical route supports repeat buying and raises switching barriers. Mid-tier brands face a harder position between Standard and Premium offerings.

Complete Report Scope:

  • By Type
    • Infant Milk Formula (0-6 Months)
    • Follow-Up Milk Formula (6-12 Months)
    • Growing-Up Milk Formula (12+ Months)
    • Specialty Formulas
  • By Category
    • Standard
    • Premium
    • Therapeutic
  • By Nature
    • Conventional
    • Organic
  • By Form
    • Powder
    • Liquid
  • By Distribution Channels
    • Supermarkets/Hypermarkets
    • Pharmacies and Drug Stores
    • Online Retail Stores
    • Other Distribution Channels
  • By Geography
    • North America
      • United States
      • Canada
      • Mexico
      • Rest of North America
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
      • Netherlands
      • Sweden
      • Poland
      • Belgium
      • Rest of Europe
    • Asia-Pacific
      • China
      • India
      • Japan
      • Australia
      • South Korea
      • Vietnam
      • Indonesia
      • Rest of Asia-Pacific
    • South America
      • Brazil
      • Argentina
      • Chile
      • Peru
      • Colombia
      • Rest of South America
    • Middle East and Africa
      • United Arab Emirates
      • Saudi Arabia
      • South Africa
      • Nigeria
      • Rest of Middle East and Africa

Geography Analysis

Asia-Pacific held 47.62% of the infant formula market size in 2026, making it the largest regional market. China remains the largest national market in the region, while India, Vietnam, Japan, and South Korea follow different demand paths. Urbanization and middle-class expansion continue to support higher-value product demand in China. China’s national standard makes compliance speed an important competitive factor. Growth in the region depends on premiumization in mature markets and wider access to packaged nutrition in developing markets.

North America is projected to grow at a 5.27% CAGR through 2032. Operation Stork Speed gives the region added attention because it seeks to diversify U.S. supply and strengthen safety oversight. Supply reliability, domestic production, and brand trust remain important concerns for parents. Canada and Mexico add regional demand, with Mexico partly supplied through U.S. channels.

Europe faces lower volume growth because births in the region declined 3.30%. Premiumization and organic-certified products from brands such as HiPP and Kendamil partly offset this pressure. South America is attracting new investment, and Nestlé announced a CHF 94.00 million infant formula facility in Ituiutaba, Brazil, as part of CHF 310.00 million in nutrition and health investment through 2028. The Middle East and Africa benefit from younger populations and urbanization, with the United Arab Emirates and Saudi Arabia serving as premium entry points. Nigeria offers volume potential as modern retail expands.


List of Companies Covered in this Report:

  • Nestlé S.A.
  • Danone S.A.
  • Abbott Laboratories
  • Yili Group
  • Reckitt Benckiser Group PLC
  • China Feihe Limited
  • Royal FrieslandCampina N.V.
  • Perrigo Company plc
  • Ausnutria Dairy Corporation Ltd.
  • The Kraft Heinz Company
  • Arla Foods amba
  • H&H Group
  • HiPP GmbH & Co. Vertrieb KG
  • Hero Group
  • Bubs Australia Limited
  • Beingmate Co., Ltd.
  • Bobbie Baby, Inc.
  • Kendal Nutricare Limited
  • Meiji Holdings Co., Ltd.
  • Morinaga Milk Industry Co., Ltd.
  • Vinamilk

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET LANDSCAPE
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising awareness of infant nutrition and development
4.2.2 Increasing demand for specialized and functional infant formula
4.2.3 Growing adoption of convenient and ready-to-feed products
4.2.4 Increasing demand for lactose-free and hypoallergenic formulas
4.2.5 Product innovation and advances in infant formula composition
4.2.6 Increasing participation of women in the workforce
4.3 Market Restraints
4.3.1 Increasing preference for breastfeeding
4.3.2 Stringent regulations governing infant formula composition and marketing
4.3.3 Product recalls and concerns regarding contamination
4.3.4 Volatility in the prices of dairy ingredients and other raw materials
4.4 Consumer Behavior Analysis
4.5 Regulatory Landscape
4.6 Technological Outlook
4.7 Porter's Five Forces Analysis
4.7.1 Bargaining Power of Suppliers
4.7.2 Bargaining Power of Buyers
4.7.3 Threat of New Entrants
4.7.4 Threat of Substitutes
4.7.5 Competitive Rivalry
5 MARKET SIZE AND GROWTH FORECASTS (VALUE AND VOLUME)
5.1 By Type
5.1.1 Infant Milk Formula (0-6 Months)
5.1.2 Follow-Up Milk Formula (6-12 Months)
5.1.3 Growing-Up Milk Formula (12+ Months)
5.1.4 Specialty Formulas
5.2 By Category
5.2.1 Standard
5.2.2 Premium
5.2.3 Therapeutic
5.3 By Nature
5.3.1 Conventional
5.3.2 Organic
5.4 By Form
5.4.1 Powder
5.4.2 Liquid
5.5 By Distribution Channels
5.5.1 Supermarkets/Hypermarkets
5.5.2 Pharmacies and Drug Stores
5.5.3 Online Retail Stores
5.5.4 Other Distribution Channels
5.6 By Geography
5.6.1 North America
5.6.1.1 United States
5.6.1.2 Canada
5.6.1.3 Mexico
5.6.1.4 Rest of North America
5.6.2 Europe
5.6.2.1 Germany
5.6.2.2 United Kingdom
5.6.2.3 France
5.6.2.4 Italy
5.6.2.5 Spain
5.6.2.6 Netherlands
5.6.2.7 Sweden
5.6.2.8 Poland
5.6.2.9 Belgium
5.6.2.10 Rest of Europe
5.6.3 Asia-Pacific
5.6.3.1 China
5.6.3.2 India
5.6.3.3 Japan
5.6.3.4 Australia
5.6.3.5 South Korea
5.6.3.6 Vietnam
5.6.3.7 Indonesia
5.6.3.8 Rest of Asia-Pacific
5.6.4 South America
5.6.4.1 Brazil
5.6.4.2 Argentina
5.6.4.3 Chile
5.6.4.4 Peru
5.6.4.5 Colombia
5.6.4.6 Rest of South America
5.6.5 Middle East and Africa
5.6.5.1 United Arab Emirates
5.6.5.2 Saudi Arabia
5.6.5.3 South Africa
5.6.5.4 Nigeria
5.6.5.5 Rest of Middle East and Africa
6 COMPETITIVE LANDSCAPE
6.1 Market Concentration
6.2 Strategic Moves
6.3 Market Share Analysis
6.4 Company Profiles (Includes Global-level Overview, Market-level Overview, Core Segments, Financials, Strategic Info, Market Rank/Share, Products & Services, Recent Developments)
6.4.1 Nestlé S.A.
6.4.2 Danone S.A.
6.4.3 Abbott Laboratories
6.4.4 Yili Group
6.4.5 Reckitt Benckiser Group PLC
6.4.6 China Feihe Limited
6.4.7 Royal FrieslandCampina N.V.
6.4.8 Perrigo Company plc
6.4.9 Ausnutria Dairy Corporation Ltd.
6.4.10 The Kraft Heinz Company
6.4.11 Arla Foods amba
6.4.12 H&H Group
6.4.13 HiPP GmbH & Co. Vertrieb KG
6.4.14 Hero Group
6.4.15 Bubs Australia Limited
6.4.16 Beingmate Co., Ltd.
6.4.17 Bobbie Baby, Inc.
6.4.18 Kendal Nutricare Limited
6.4.19 Meiji Holdings Co., Ltd.
6.4.20 Morinaga Milk Industry Co., Ltd.
6.4.21 Vinamilk
7 MARKET OPPORTUNITIES AND FUTURE OUTLOOK

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • Nestlé S.A.
  • Danone S.A.
  • Abbott Laboratories
  • Yili Group
  • Reckitt Benckiser Group PLC
  • China Feihe Limited
  • Royal FrieslandCampina N.V.
  • Perrigo Company plc
  • Ausnutria Dairy Corporation Ltd.
  • The Kraft Heinz Company
  • Arla Foods amba
  • H&H Group
  • HiPP GmbH & Co. Vertrieb KG
  • Hero Group
  • Bubs Australia Limited
  • Beingmate Co., Ltd.
  • Bobbie Baby, Inc.
  • Kendal Nutricare Limited
  • Meiji Holdings Co., Ltd.
  • Morinaga Milk Industry Co., Ltd.
  • Vinamilk